Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 06.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | xchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certa |
| 11.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 26.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ion 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 01.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 02.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 23.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 11.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 10.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Unternehmen & Branche
| Name | Talis Biomedical Corp |
|---|---|
| Ticker | TLIS |
| CIK | 0001584751 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3826 · Laboratory Analytical Instruments |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 5,2 Mio. USD |
| Beta | 1,32 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2024-06-30 | 10-Q | 0 | -8,849,000 | -4.86 | 72,699,000 | 48,626,000 |
| 2024-03-31 | 10-Q | 73,000 | -13,035,000 | -7.15 | 82,494,000 | 56,684,000 |
| 2023-12-31 | 10-K | 2,134,000 | -62,007,000 | -34.12 | 94,674,000 | 69,116,000 |
| 2023-09-30 | 10-Q | 140,000 | -15,682,000 | -8.62 | 107,228,000 | 81,556,000 |
| 2023-06-30 | 10-Q | 581,000 | -15,034,000 | -8.27 | 123,076,000 | 96,166,000 |
| 2023-03-31 | 10-Q | 1,218,000 | -17,831,000 | -9.84 | 133,053,000 | 110,124,000 |
| 2022-12-31 | 10-K | 4,812,000 | -113,012,000 | -62.77 | 169,290,000 | 126,739,000 |
| 2022-09-30 | 10-Q | 796,000 | -26,021,000 | -14.44 | 194,094,000 | 152,386,000 |
| 2022-06-30 | 10-Q | 572,000 | -27,011,000 | -15.01 | 221,690,000 | 177,019,000 |
| 2022-03-31 | 10-Q | 3,187,000 | -33,051,000 | -1.25 | 230,587,000 | 202,785,000 |
| 2021-12-31 | 10-K | 8,193,000 | -192,036,000 | -8.48 | 265,828,000 | 233,977,000 |
| 2021-09-30 | 10-Q | 218,000 | -38,418,000 | -1.49 | 303,096,000 | 258,792,000 |
| 2021-06-30 | 10-Q | 117,000 | -64,472,000 | 379,538,000 | 293,732,000 | |
| 2021-03-31 | 10-Q | 7,000,000 | -60,492,000 | 403,182,000 | 356,333,000 | |
| 2020-12-31 | 10-K | -91,130,000 | 198,405,000 | -108,571,000 | ||
| 2020-09-30 | 10-Q | -29,514,000 | -65,942,000 | |||
| 2020-06-30 | 10-Q | -10,046,000 | -37,466,000 | |||
| 2020-03-31 | 10-Q | -7,374,000 | -27,828,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.